Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (125)
- Compliance and enforcement (33)
- Import and export (30)
- Shortages and supply disruptions (16)
- Sunscreens (9)
- Advertising (6)
- COVID-19 (5)
- Labelling and packaging (4)
- Weight loss products (4)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Cosmetics (1)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
1291 result(s) found, displaying 701 to 725
-
Market actionsRecall for product correction due to fire risk from faulty component.
-
Market actionsRecall for product correction due to fire risk from faulty component.
-
Market actionsThe following medicines (with brand names in brackets) should be returned to a pharmacy: alprazolam (Xanax), cabergoline (Dostinex and Cabaser), mefanamic acid (Ponstan), methotrexate (Methoblastin) and triazolam (Halcion)
-
Market actionsRecall - bottles supplied without child-resistant caps
-
Market actionsRecall for product correction due to risk of sparking or fire due to damaged or cut wire.
-
-
Market actionsRecall for product correction due to potential for insulin to not be delivered as intended.
-
Market actionsRecall due to counterfeit products may have defects and not be effective.
-
-
-
-
-
-
-
Market actionsUpdate - recall for product correction - advertisements published to inform all affected users
-
-
-
Market actionsRecall due to incorrect contact lenses supplied to some consumers.
-
Market actionsRecall due to risk of adverse events due to potential dilution.
-
-
-
Safety alertsSafety advisory
-
Safety alertsSafety alert due to higher-than-expected revision rate when used without patella resurfacing.
-
Market actionsHazard alert due to higher-than-expected revision rate.
-
Market actionsHazard alert due to potential for implant failure due to loosening.